Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro
- PMID: 1941122
- DOI: 10.3171/jns.1991.75.6.0922
Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro
Abstract
Lysis of tumor cells by activated cytotoxic lymphocytes requires their recognition of antigens associated with major histocompatibility complex molecules. The authors studied the constitutive expression of Class I and Class II major histocompatibility complex antigens on mouse brain-tumor cells and the capacity of different cytokines and cytokine combinations to alter this expression in vitro. Cells from the murine glioma 26 (GL26), glioma 261 (GL261), and ependymoblastoma A (EpA) cell lines were established in monolayer culture and treated for 48 hours with either alpha interferon, gamma interferon, tumor necrosis factor alpha, tumor necrosis factor alpha plus gamma interferon, or interleukin-2. They were then analyzed by flow cytometry for baseline and cytokine-altered major histocompatibility complex expression. All cell lines had a similar constitutive major histocompatibility complex pattern with low Class I antigen expression and no detectable Class II antigen expression. Alpha interferon substantially induced and up-regulated Class I antigen expression, but had no effect on Class II antigen expression. Gamma interferon also stimulated up-regulation of Class I antigen expression, generally doubling the anti-Class I antigen fluorescence of treated cells. Its effect on Class II antigen expression was more extensive. In the GL26 and GL261 cell lines the expression of Class II antigen determinants increased to 12 x and 14 x control values and as many as 75% of cells that had no detectable constitutive expression of Class II antigen expressed this antigen after priming with gamma interferon. The addition of tumor necrosis factor alpha to gamma interferon further increased Class II antigen expression on EpA tumor cells only. Interleukin-2 and tumor necrosis factor alpha alone had no effect on Class I or Class II antigen expression of any cell lines. It is concluded that Class I and Class II antigen expression in mouse glioma cell lines is induced and enhanced after treatment with certain cytokines in vitro. Use of these cell lines to create in situ primary brain tumors in C57BL/6 mice should provide an excellent animal system to study major histocompatibility complex modulation in brain tumor cells and to examine the potential impact of major histocompatibility complex up-regulation on the response of brain tumors to immunotherapy.
Comment in
-
Major histocompatibility antigens in murine tumors.J Neurosurg. 1992 Jun;76(6):1048-50. doi: 10.3171/jns.1992.76.6.1048. J Neurosurg. 1992. PMID: 1588418 No abstract available.
Similar articles
-
Lytic susceptibility of target cells to cytotoxic T cells is determined by their constitutive major histocompatibility complex class I antigen expression and cytokine-induced activation status.Immunology. 1994 Apr;81(4):569-77. Immunology. 1994. PMID: 7913694 Free PMC article.
-
Schwann cells co-cultured with stimulated T cells and antigen express major histocompatibility complex (MHC) class II determinants without interferon-gamma pretreatment: synergistic effects of interferon-gamma and tumor necrosis factor on MHC class II induction.Eur J Immunol. 1989 Jan;19(1):177-83. doi: 10.1002/eji.1830190128. Eur J Immunol. 1989. PMID: 2493382
-
Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro.Cancer Res. 1988 Oct 15;48(20):5818-24. Cancer Res. 1988. PMID: 3139284
-
Interferon-gamma induces the expression of H-2 and Ia antigens on brain cells.J Neuroimmunol. 1985 Feb-Mar;7(5-6):255-78. doi: 10.1016/s0165-5728(84)80026-0. J Neuroimmunol. 1985. PMID: 3919057 Review. No abstract available.
-
Immunotherapy of brain tumors.J Neurosurg Sci. 1990 Jul-Dec;34(3-4):265-78. J Neurosurg Sci. 1990. PMID: 2098505 Review.
Cited by
-
Developing a Tanshinone IIA Memetic by Targeting MIOS to Regulate mTORC1 and Autophagy in Glioblastoma.Int J Mol Sci. 2024 Jun 14;25(12):6586. doi: 10.3390/ijms25126586. Int J Mol Sci. 2024. PMID: 38928292 Free PMC article.
-
The novel immunotherapeutic molecule T11TS modulates glioma-induced changes of key components of the immunological synapse in favor of T cell activation and glioma abrogation.J Neurooncol. 2014 Oct;120(1):19-31. doi: 10.1007/s11060-014-1528-9. Epub 2014 Jul 16. J Neurooncol. 2014. PMID: 25026997
-
Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy.Cancer Sci. 2006 Jun;97(6):546-53. doi: 10.1111/j.1349-7006.2006.00208.x. Cancer Sci. 2006. PMID: 16734735 Free PMC article.
-
Evaluation of TgH(CX3CR1-EGFP) mice implanted with mCherry-GL261 cells as an in vivo model for morphometrical analysis of glioma-microglia interaction.BMC Cancer. 2016 Feb 8;16:72. doi: 10.1186/s12885-016-2118-3. BMC Cancer. 2016. PMID: 26856327 Free PMC article.
-
Experimental models and tools to tackle glioblastoma.Dis Model Mech. 2019 Sep 6;12(9):dmm040386. doi: 10.1242/dmm.040386. Dis Model Mech. 2019. PMID: 31519690 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials